Skip To Main Content
R. A. Barker on Muck Rack

R. A. Barker

As seen in: Nature, Brain
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with R. A.

Contact R. A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

|
By G. S. Paul, R. F. Smith, A. Mark Evans, B. Harry, E. Cutting, O. Hansson, M. K. B. Parmar, R. A. Barker, H. Bjartmarz, A. Kirkeby, J. Nelander, S. Kayhanian, S. Fazal, N. P. Lao-Kaim, T. van Vliet, S. Ullén, I. Grubor, P. Piccini, O. Lindvall, A. Björklund, H. Widner
| Nature Verified
Abstract Parkinson’s disease (PD) is characterized by progressive loss of nigral dopaminergic neurons, resulting in disabling motor symptoms. Intracerebral transplantation of stem cell-derived dopaminergic progenitors to replace lost endogenous dopaminergic neurons offers a new potentially restorative therapeutic approach for PD.
Open in Who Shared Issue with article?

Biomarkers and Parkinson's disease

|
By A. W. Michell, T. Foltynie, R. A. Barker
| Brain Verified
Why do we need a marker for Parkinson's disease? To improve diagnosis To many, the most intuitive goal for a biomarker is to help diagnose disease. For Parkinson's disease this may be divided into two separate aims: differentiation of susceptible individuals from normals before symptoms develop (sensitivity), and identification of true idiopathic Parkinson's disease from its imitators once symptomatic (specificity).
Open in Who Shared Issue with article?
See all 2 articles